Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Sep;94(9):1147-53.
doi: 10.1136/hrt.2007.137919. Epub 2008 Apr 1.

Administration of intracoronary bone marrow mononuclear cells on chronic myocardial infarction improves diastolic function

Affiliations
Randomized Controlled Trial

Administration of intracoronary bone marrow mononuclear cells on chronic myocardial infarction improves diastolic function

K Yao et al. Heart. 2008 Sep.

Abstract

Background: Regeneration of the myocardium and improved ventricular function have been demonstrated in patients with acute myocardial infarction (MI) treated by intracoronary delivery of autologous bone marrow mononuclear cells (BMC) a few days after successful myocardial reperfusion by percutaneous coronary intervention (PCI); however, the effects of intracoronary cell infusion in chronic MI patients are still unknown.

Aims: To investigate whether intracoronary infusion of BMC into the infarct-related artery in patients with healed MI could lead to improvement in left ventricular (LV) function.

Methods: Among 47 patients with stable ischaemic heart disease due to a previous MI (13 (SD 8) months previously), 24 were randomised to intracoronary infusion of BMC (BMC group) and 23 to a saline infusion (control group) into the target vessel after successful PCI within 12 hours after chest pain occurred. LV systolic and diastolic function, infarct size and myocardial perfusion defect were assessed with the use of echocardiography, magnetic resonance imaging (MRI) or (201)Tl single-photon-emission computed tomography (SPECT) at baseline and repeated at the 6-month follow-up examination.

Results: BMC treatment did not result in a significant increase in LV ejection fraction in any of the groups by any of the methods used, and the apparent tendency of an improvement was not statistically different between the two groups. The two groups also did not differ significantly in changes of LV end-diastolic and systolic volume, infarct size or myocardial perfusion. However, there was an overall effect of BMC transfer compared with the control group with respect to early/late (E/A) (p<0.001), early diastolic velocity/late diastolic (Aa) velocity (Ea/Aa) ratio (p = 0.002) and isovolumetric relaxation time (p = 0.038) after 6 months, as evaluated by tissue Doppler echocardiography. We noted no complications associated with BMS transfer.

Conclusion: Intracoronary transfer of autologous BMC in patients with healed MI did not lead to significant improvement of cardiac systolic function, infarct size or myocardial perfusion, but did lead to improvement in diastolic function.

PubMed Disclaimer

Similar articles

Cited by

  • A role of myocardial stiffness in cell-based cardiac repair: a hypothesis.
    Zhang S, Sun A, Liang Y, Chen Q, Zhang C, Wang K, Zou Y, Ge J. Zhang S, et al. J Cell Mol Med. 2009 Apr;13(4):660-3. doi: 10.1111/j.1582-4934.2009.00710.x. Epub 2009 Feb 20. J Cell Mol Med. 2009. PMID: 19243474 Free PMC article.
  • Global position paper on cardiovascular regenerative medicine.
    Fernández-Avilés F, Sanz-Ruiz R, Climent AM, Badimon L, Bolli R, Charron D, Fuster V, Janssens S, Kastrup J, Kim HS, Lüscher TF, Martin JF, Menasché P, Simari RD, Stone GW, Terzic A, Willerson JT, Wu JC; TACTICS (Transnational Alliance for Regenerative Therapies in Cardiovascular Syndromes) Writing Group; Authors/Task Force Members. Chairpersons; Basic Research Subcommittee; Translational Research Subcommittee; Challenges of Cardiovascular Regenerative Medicine Subcommittee; Tissue Engineering Subcommittee; Delivery, Navigation, Tracking and Assessment Subcommittee; Clinical Trials Subcommittee; Regulatory and funding strategies subcommittee; Delivery, Navigation, Tracking and Assessment Subcommittee. Fernández-Avilés F, et al. Eur Heart J. 2017 Sep 1;38(33):2532-2546. doi: 10.1093/eurheartj/ehx248. Eur Heart J. 2017. PMID: 28575280 Free PMC article. Review. No abstract available.
  • Cellular Therapy for Heart Failure.
    Psaltis PJ, Schwarz N, Toledo-Flores D, Nicholls SJ. Psaltis PJ, et al. Curr Cardiol Rev. 2016;12(3):195-215. doi: 10.2174/1573403x12666160606121858. Curr Cardiol Rev. 2016. PMID: 27280304 Free PMC article. Review.
  • Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions.
    Sanganalmath SK, Bolli R. Sanganalmath SK, et al. Circ Res. 2013 Aug 30;113(6):810-34. doi: 10.1161/CIRCRESAHA.113.300219. Circ Res. 2013. PMID: 23989721 Free PMC article. Review.
  • Stem cell therapy for chronic ischaemic heart disease and congestive heart failure.
    Fisher SA, Doree C, Mathur A, Taggart DP, Martin-Rendon E. Fisher SA, et al. Cochrane Database Syst Rev. 2016 Dec 24;12(12):CD007888. doi: 10.1002/14651858.CD007888.pub3. Cochrane Database Syst Rev. 2016. PMID: 28012165 Free PMC article.

Publication types

MeSH terms